No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease

Autor: Jon-Magnus Tangen, Herman Nilsson-Ehle, Eva Hellström-Lindberg, Ingemar Winquist, Ulf Tidefelt, Robert Hast, Olle Linder, G. Gahrton, Inger Marie S. Dahl, Ingela Turesson, L Ohm, Per Bernell, Gunnar Öberg, C. Paul, Jonas Wallvik, Magnus Björkholm, Richard Lerner, Fredrik Celsing, Greger Lindberg, Eva Löfvenberg, J. Samuelsson, Anders Wahlin, I. Dybedal
Rok vydání: 2003
Předmět:
Zdroj: Leukemia. 17:1827-1833
ISSN: 1476-5551
0887-6924
Popis: In this prospective randomized multicenter trial 93 patients, median age 72 years, with RAEB-t (n=25) and myelodysplastic syndrome (MDS)-AML (n=68) were allocated to a standard induction chemotherapy regimen (TAD 2+7) with or without addition of granulocyte-macrophage-CSF (GM-CSF). The overall complete remission (CR) rate was 43% with no difference between the arms. Median survival times for all patients, CR patients, and non-CR patients were 280, 550, and 100 days, respectively, with no difference between the arms. Response rates were significantly better in patients with serum lactate dehydrogenase (S-LDH) levels
Databáze: OpenAIRE